<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1997
or
_____ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO ______
Commission File Number: 0-22352
----------------------
HOLOPHANE CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
----------------------
DELAWARE 31-1288751
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
250 EAST BROAD STREET
SUITE 1400
COLUMBUS, OHIO
43215
(Address of principal executive offices)
(614) 224-3134
Registrant's telephone number, including area code
----------------------
Indicate by check mark whether the registrant (1) has filed all reports to
be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [x] No [ ]
The number of shares outstanding of registrant's Common Stock as of June
30 1997: 11,322,248
<PAGE>
HOLOPHANE CORPORATION
FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 1997
INDEX
PART I. FINANCIAL INFORMATION
Condensed Consolidated Statements of Income for the three
months ended June 30, 1997 and June 30, 1996 (unaudited) . . . 1
Condensed Consolidated Statements of Income for the six months
ended June 30, 1997 and June 30, 1996 (unaudited). . . . . . . 2
Condensed Consolidated Balance Sheets as of June 30, 1997
(unaudited) and December 31, 1996. . . . . . . . . . . . . . . 3
Condensed Consolidated Statements of Cash Flows for the six
months ended June 30, 1997 and June 30, 1996 (unaudited) . . . 4
Condensed Consolidated Statement of Stockholders' Equity as of
June 30, 1997 (unaudited). . . . . . . . . . . . . . . . . . . 5
Notes to Condensed Consolidated Financial Statements . . . . . 6
Management Discussion and Analysis . . . . . . . . . . . . . . 7-8
PART II. OTHER INFORMATION. . . . . . . . . . . . . . . . . . . . . . . 9-10
Signature . . . . . . . . . . . . . . . . . . . . . . . . . . 11
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands except per share data)
Three Month Period Ended
---------------------------
June 30, June 30,
1997 1996
- --------------------------------------------------------------------------------
Net Sales $48,607 $44,605
Cost of Goods Sold 29,853 27,421
------- -------
Gross Margin 18,754 17,184
Selling and Administrative Expenses 10,510 9,347
Research and Development 1,527 1,358
Other Expenses 215 143
------- -------
Operating Income 6,502 6,336
Interest Expense 429 562
Interest Income (96) (112)
------- -------
Income Before Income Taxes 6,169 5,886
Provision for Income Taxes 2,251 2,246
------- -------
Net Income 3,918 3,640
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Primary Earnings Per Share $0.34 $0.31
- --------------------------------------------------------------------------------
Fully Diluted Earnings Per Share $0.34 $0.31
- --------------------------------------------------------------------------------
Weighted Average Number of Shares Outstanding 11,672 11,714
- --------------------------------------------------------------------------------
The accompanying notes are an integral part of these consolidated financial
statements.
1
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands except per share data)
Six Month Period Ended
---------------------------
June 30, June 30,
1997 1996
- --------------------------------------------------------------------------------
Net Sales $95,015 $82,661
Cost of Goods Sold 58,379 51,565
------- -------
Gross Margin 36,636 31,096
Selling and Administrative Expenses 21,381 18,284
Research and Development 2,994 2,793
Other Expenses 383 106
------- -------
Operating Income 11,878 9,913
Interest Expense 907 1,138
Interest Income (193) (282)
------- -------
Income Before Income Taxes 11,164 9,057
Provision for Income Taxes 4,136 3,464
------- -------
Net Income 7,028 5,593
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Primary Earnings Per Share $0.60 $0.48
- --------------------------------------------------------------------------------
Fully Diluted Earnings Per Share $0.60 $0.48
- --------------------------------------------------------------------------------
Weighted Average Number of Shares Outstanding 11,733 11,769
- --------------------------------------------------------------------------------
The accompanying notes are an integral part of these consolidated financial
statements.
2
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
($ in thousands) (Unaudited)
June 30 December 31
1997 1996
- --------------------------------------------------------------------------------
ASSETS
- --------------------------------------------------------------------------------
Cash and Equivalents $13,761 $8,072
Receivables 28,831 33,104
Inventory 14,345 13,302
Prepaid and Other Deferred Expenses 3,800 3,848
- --------------------------------------------------------------------------------
TOTAL CURRENT ASSETS 60,737 58,326
- --------------------------------------------------------------------------------
Property, Plant and Equipment, Net 39,265 39,413
Goodwill, Net 21,016 21,276
Other Assets 5,320 4,952
- --------------------------------------------------------------------------------
TOTAL ASSETS $126,338 $123,967
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
Current Liabilities $32,993 $31,137
Long Term Debt 15,671 18,866
Other Long Term Liabilities 6,695 6,820
Stockholders' Equity 70,979 67,144
- --------------------------------------------------------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $126,338 $123,967
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
The accompanying notes are an integral part of these consolidated financial
statements.
3
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited $ in thousands)
Six Month Period Ended
----------------------
June 30 June 30
1997 1996
- --------------------------------------------------------------------------------
Net cash flow provided by operating activities $17,143 $7,129
- --------------------------------------------------------------------------------
Investing activities:
Capital expenditures (3,445) (2,146)
Other (695) (356)
- --------------------------------------------------------------------------------
Net cash used in investing activities (4,140) (2,502)
- --------------------------------------------------------------------------------
Financing activities:
Principal payments of long term debt (3,188) (3,147)
Purchase of treasury shares (4,133) (1,871)
Proceeds from the sales of treasury shares 13 278
- --------------------------------------------------------------------------------
Net cash used in financing activities (7,308) (4,740)
- --------------------------------------------------------------------------------
Effects of exchange rate changes on cash (6) 13
- --------------------------------------------------------------------------------
Net increase/(decrease) in cash and equivalents 5,689 (100)
- --------------------------------------------------------------------------------
Cash and equivalents at beginning of period 8,072 13,356
- --------------------------------------------------------------------------------
Cash and equivalents at end of period $13,761 $13,256
- --------------------------------------------------------------------------------
The accompanying note is an integral part of these consolidated financial
statements.
4
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
(Unaudited $ in thousands)
<TABLE>
<CAPTION>
COMMON STOCK ADDITIONAL TREASURY STOCK CUMULATIVE
--------------------- PAID-IN RETAINED ------------------- TRANSLATION STOCKHOLDERS'
SHARES AMOUNT CAPITAL EARNINGS SHARES AMOUNT ADJUSTMENTS EQUITY
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1996 11,895,861 $119 $43,801 $30,527 473,369 ($6,534) ($769) $67,144
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
Net income for the year 7,028 7,028
Shares used in acquisition 13 (71,725) 1,367 1,380
Purchase of treasury shares 212,908 (4,529) (4,529)
Stock options exercised,
including related tax benefits (461) (40,939) 873 412
Translation adjustments (456) (456)
- -----------------------------------------------------------------------------------------------------------------------------------
BALANCE AT JUNE 30, 1997 11,895,861 $119 $43,353 $37,555 573,613 ($8,823) ($1,225) $70,979
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
5
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BASIS OF PRESENTATION - The condensed consolidated balance sheet as of June 30,
1997, the condensed consolidated statements of income for the three months ended
June 30, 1997 and June 30, 1996 and the condensed consolidated statements of
income, cash flows and stockholders' equity for the six months ended June 30,
1997 and June 30, 1996 have been prepared by the Company, without audit. In the
opinion of management, all adjustments, which include only normal recurring
adjustments, necessary to present fairly the financial position, results of
operations, changes in stockholders' equity and changes in cash flows for all
periods presented have been made.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. These consolidated financial statements should
be read in conjunction with the financial statements and notes thereto included
in the Company's December 31, 1996 annual report on Form 10-K. The results of
operations for the six month period ended June 30, 1997 are not necessarily
indicative of the operating results for the full year.
CLASSIFICATION OF INVENTORY
(in thousands)
(Unaudited)
June 30, December 31,
1997 1996
----------- ------------
Raw Materials $ 9,314 $ 7,997
Work in Process 3,757 3,620
Finished Goods 2,062 2,374
------- -------
TOTAL 15,133 13,991
Less Valuation Allowance (788) (689)
------- -------
TOTAL $14,345 $13,302
------- -------
------- -------
6
<PAGE>
MANAGEMENT DISCUSSION AND ANALYSIS
COMPARISON OF SECOND QUARTER 1997 TO SECOND QUARTER 1996
Worldwide net sales for the second quarter of 1997 were $48.6 million, up $4.0
million, or 9% from second quarter 1996. All of the growth in sales came from
the addition of the MetalOptics product line acquired in September 1996.
Including MetalOptics, U.S. sales increased 9% compared to 1996. Internal sales
growth in the United States was off approximately 3% from 1996 when the large
Atlanta Olympic project was underway. European sales in local currency were up
5% compared to last year due to stronger demand for the Company's products.
Canadian sales were up 13% in local currency in 1997 compared to 1996 due to
stronger business conditions.
Operating income was $6.5 million up from $6.3 million. The increase in
operating income was due to higher sales volume, somewhat offset by higher
operating expenses compared to 1996.
The $0.1 million decrease in net interest expense principally resulted from
lower average outstanding indebtedness.
Second quarter net income and earnings per common share were $3.9 million and
$0.34, respectively, compared with $3.6 million and $0.31 in 1996.
COMPARISON OF FIRST SIX MONTHS 1997 TO FIRST SIX MONTHS 1996
Net sales for the 1997 period were $95.0 million, up $12.4 million or
approximately 15% from the same period in 1996. Including MetalOptics, U.S.
sales were up 18% from prior year. Internal sales growth for the U.S. for the
year is 5%. In local currencies, European sales have decreased 2% compared to
the prior year period and Canadian sales have increased 2% compared to 1996.
Operating income in 1997 was $11.9 million compared to $9.9 million in 1996.
The increase in operating income is due to higher volume, somewhat offset by
higher operating expenses in 1997.
Net interest expense was $0.7 million in 1997 compared to $0.9 million in 1996.
The decrease in interest expense was due to lower outstanding debt balances.
Net income and earnings per common share for the first six months of 1997 were
$7.0 million and $0.60, respectively, compared to $5.6 million and $0.48 in
1996.
7
<PAGE>
CAPITAL RESOURCES AND LIQUIDITY
Working capital was $27.7 million as of June 30, 1997, up $0.6 million from
year-end 1996 due to higher cash balances offset by volume related decreases in
receivables and higher current liabilities.
Cash on hand, funds generated from operations and amounts available under the
Credit Agreement are expected to adequately fulfill Holophane's anticipated
requirements for the remainder of 1997.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: Except for historical information contained herein, the matters set forth
in this filing constitute forward-looking statements that are dependent on
certain risks and uncertainties including such factors, among others, as weather
conditions throughout the remainder of the fiscal year, the general state of the
national economy and other risks detailed in the Company's Securities Exchange
Act of 1934 filings.
8
<PAGE>
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Not Applicable.
ITEM 2. CHANGES IN SECURITIES
Not Applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not Applicable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
(a) On May 6, 1997, Holophane Corporation held its annual meeting of
stockholders (the "Annual Meeting"). At the close of business on the
record date, 11,354,516 share of Common Stock were outstanding and
entitle to vote at the Annual Meeting. At the Annual Meeting,
9,714,315, or 85.6% of the outstanding shares of Common Stock entitled
to vote were represented in person or by proxy.
(b) Directors elected at the Annual Meeting:
William R. Michaels and Robert L. Purdum
9,647,137 For 67,178 Withheld
Directors whose term of office as a director continued after the
Annual Meeting:
John R. DallePezze, Anthony P. Scotto and Jeffrey M. Wilkins
(c) See Item 4(b) for the voting results for directors.
Proposal to ratify the selection of Deloitte & Touche LLP as the
auditors of Holophane Corporation for the 1997 fiscal year:
9,694,401 For 600 Against 19,314 Abstain and Broker Non-Vote
Each proposal was approved by more than the requisite number of
stockholders.
9
<PAGE>
ITEM 5. OTHER INFORMATION
Not Applicable.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
Not Applicable.
10
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Holophane
has duly caused this report to be signed on its behalf of the undersigned
thereunto duly authorized.
HOLOPHANE CORPORATION
(Registrant)
DATE: July 17, 1997 /s/ Bruce A. Philp
---------------------- ------------------------------------------
Bruce A. Philp
Vice President, Finance and
Chief Financial Officer
11
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> JUN-30-1997
<CASH> 13,761
<SECURITIES> 0
<RECEIVABLES> 29,836
<ALLOWANCES> 1,005
<INVENTORY> 14,345
<CURRENT-ASSETS> 60,737
<PP&E> 85,610
<DEPRECIATION> 46,345
<TOTAL-ASSETS> 126,338
<CURRENT-LIABILITIES> 32,993
<BONDS> 15,671
0
0
<COMMON> 119
<OTHER-SE> 70,860
<TOTAL-LIABILITY-AND-EQUITY> 126,338
<SALES> 95,015
<TOTAL-REVENUES> 95,015
<CGS> 58,379
<TOTAL-COSTS> 24,375
<OTHER-EXPENSES> 383
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 907
<INCOME-PRETAX> 11,164
<INCOME-TAX> 4,136
<INCOME-CONTINUING> 7,028
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 7,028
<EPS-PRIMARY> 0.60
<EPS-DILUTED> 0.60
</TABLE>
